Evaluation of the diagnostic value of dual-time-point, multi-parameter 99mTc-PYP imaging in diagnosing Transthyretin Cardiac Amyloidosis Authors: Jinyong Luo, Lihua Ji, Qingfei Dong, Qingqian Kong, Ting Chen, Weihong Yuan Published: 2026 ABSTRACT AbstractObjective To assess the clinical value of dual-time-point planar imaging and SPECT/CT tomographic imaging of 99mTc-PYP in diagnosing transthyretin cardiac amyloidosis (ATTR-CA), and to compare the diagnostic performance of different imaging time points and methods. Methods A retrospective analysis of 98 suspected CA patients (ATTR-CA 12; AL-CA 23; non-CA 63). Early imaging at 1 h and delayed imaging at 3 h included planar and tomographic imaging. Evaluations used the Perugini visual grading, heart-to-contralateral lung uptake ratio (H/CL), and tomographic semi-quantitative scoring. Pathology biopsy and genetic testing served as the gold standard. Sensitivity, specificity, and accuracy were compared across methods. Results Delayed tomographic imaging for ATTR-CA achieved a sensitivity of 100.0%, specificity of 96.5%, and accuracy of 96.9%, the best among all methods. The earliest Perugini scoring method had the lowest accuracy (80.6%), and early imaging using the H/CL method had the lowest diagnostic sensitivity (58.3%). SPECT/CT imaging at 3 h provides significant incremental diagnostic value compared to planar imaging and offers the greatest benefits, Cases that were missed during the initial review have been reclassified.Delayed imaging was superior to early imaging overall, and tomographic imaging significantly reduced false positives caused by blood-pool artifacts. Conclusion Dual-time-point 99mTc-PYP imaging with tomographic imaging can significantly improve the diagnostic accuracy for ATTR-CA, with delayed SPECT/CT performing best. For cases with atypical early imaging or diagnostic difficulty due to blood-pool tracer distribution, when Perugini grade is 2, early H/CL ≤ 1.5 or delayed H/CL ≤ 1.3, or in highly suspected cases where early imaging provides insufficient diagnostic evidence, routine inclusion of delayed SPECT/CT in the imaging workflow for suspected ATTR-CA is recommended to optimize subtyping and guide subsequent therapy.Keywords: 99mTc-PYP, Cardiac amyloidosis, Transthyretin, Diagnostic performance Background Cardiac amyloidosis (CA) is a rare disorder characterized by the extracellular deposition of insoluble fibrillar aggregates formed from misfolded protein precursors within the myocardial interstitium, resulting in a clinical syndrome predominantly manifested by heart failure, arrhythmias, and myocardial ischemia [1]. The onset of CA is often insidious, making early identification particularly challenging. According to the type of precursor proteins deposited in the myocardium, CA can be classified into transthyretin-type (ATTR), light-chain-type (AL), and other rare forms. Among these, ATTR-CA and AL-CA together account for more than 95% of cases, yet their therapeutic strategies and prognoses differ substantially [2]. Based on transthyretin (TTR) gene mutation status, ATTR-CA can be further subdivided into wild-type ATTR-CA (ATTRwt-CA) and mutant-type ATTR-CA (ATTRm-CA). ATTRm-CA is an autosomal dominant hereditary disease that often exhibits geographic or ethnic clustering [3]. However, the clinical manifestations of CA are largely nonspecific and frequently overlap with those of other cardiovascular conditions, such as aortic stenosis and coronary artery disease. As a result, CA is associated with high rates of misdiagnosis and underdiagnosis. Previous studies have reported misdiagnosis rates of ATTR-CA ranging from 34% to 57% [4], leading to delayed diagnosis and initiation of appropriate therapy. In untreated patients with ATTR-CA, the median survival ranges from 2.5 to 3.6 years [4–6]. In recent years, the emergence of disease-modifying therapies, particularly tafamidis, has demonstrated significant survival benefits in patients with ATTR-CA, underscoring the critical importance of early recognition and accurate diagnosis [7]. Although echocardiography and contrast-enhanced cardiac magnetic resonance imaging can provide important diagnostic clues suggestive of cardiac amyloidosis, their ability to reliably differentiate CA subtypes remains limited. In recent years, advances in nuclear medicine have provided a reliable noninvasive approach for the etiological typing of transthyretin cardiac amyloidosis (ATTR-CA). 99mTc-pyrophosphate (99mTc-PYP) imaging, a radiopharmaceutical widely used in clinical bone scintigraphy, has been shown to selectively bind to transthyretin-type amyloid fibrillar deposits in the myocardium, whereas uptake in light-chain cardiac amyloidosis (AL-CA) is significantly lower. Multiple international multicenter studies have demonstrated that, after exclusion of AL-CA, 99mTc-PYP imaging achieves a sensitivity and specificity exceeding 95% for the diagnosis of ATTR-CA. Its clinical utility has been formally recognized in the consensus statements of the American Society of Nuclear Cardiology (ASNC) and the guidelines of the European Society of Cardiology (ESC) [8]. In addition, standardized domestic technical operation guidelines for this examination were published in March 2022 [9]. To reduce the risk of misdiagnosis, recent recommendations advocate the addition of SPECT/CT tomographic fusion imaging to conventional planar imaging in order to confirm true myocardial tracer deposition and to differentiate it from residual blood-pool activity. The combination of dual-time-point planar imaging with tomographic imaging offers clear diagnostic advantages and has the potential to significantly improve diagnostic accuracy. However, the relative clinical value of different imaging time points and image assessment methods has not yet been systematically compared. Therefore, the present study aims to comprehensively evaluate and compare the diagnostic performance of early versus delayed imaging, as well as planar versus tomographic imaging, in the diagnosis of ATTR-CA. To our knowledge, this is the first study to systematically assess diagnostic performance across different imaging time points and imaging modalities, thereby providing evidence to support the establishment of a more rational and standardized imaging workflow. Methods Patient population This retrospective study included 98 patients with clinically suspected cardiac amyloidosis (CA) who were treated at Yunnan Fuwai Cardiovascular Hospital between May 2021 and January 2025. Endomyocardial biopsy and genetic testing have been adopted as the definitive gold standards for the diagnosis of cardiac amyloidosis (CA) [10]. Patients with highly suspected CA were collected for biopsy samples from different parts of tissues on a randomized basis. Patients with highly suspected CA were sampled on a randomized basis. Of these, 12 patients were confirmed to have transthyretin cardiac amyloidosis (ATTR‑CA). Among them, three were diagnosed by endomyocardial biopsy, two by abdominal subcutaneous fat‑pad biopsy, and one underwent fat‑pad biopsy followed by confirmatory myocardial biopsy due to an initial inconclusive result. Six patients were confirmed by genetic testing. This group included 8 males and 4 females, aged 21–85 years, with a mean age of 56.5 ± 9.8 years. Twenty‑three patients were diagnosed with light chain cardiac amyloidosis (AL‑CA). Among them, four were confirmed by endomyocardial biopsy, thirteen by abdominal subcutaneous fat‑pad biopsy, and six by combined fat‑pad biopsy and bone‑marrow aspiration. This group included 15 males and 8 females, aged 21–85 years, with a mean age of 57.3 ± 10.1 years. The remaining 63 patients were classified as non-CA, including 41 males and 22 females, aged 27–87 years, with a mean age of 61.5 ± 16.6 years. All patients demonstrated negative results on serum free light-chain assays and immunofixation electrophoresis, and all 99mTc-PYP scintigraphy findings were negative. Clinical manifestations included fatigue, chest tightness, and bilateral lower-extremity edema in 44 patients; palpitations, dyspnea, and lower-extremity edema in 17 patients; limb and joint pain in 12 patients; amyloid-related renal involvement in 6 patients; and intermittent transient visual loss (amaurosis fugax) in 4 patients. The inclusion criteria were as follows: Heart failure of unknown etiology with a left ventricular ejection fraction < 50%; Heart failure of unknown etiology with a left ventricular ejection fraction < 50%; Completion of dual-time-point planar imaging and SPECT imaging with 99mTc-PYP; Completion of dual-time-point planar imaging and SPECT imaging with 99mTc-PYP; A final clinical diagnosis of CA or definitive exclusion of CA; A final clinical diagnosis of CA or definitive exclusion of CA; Completion of serum and/or urine immunofixation electrophoresis (IFE) or free light-chain (FLC) testing. Completion of serum and/or urine immunofixation electrophoresis (IFE) or free light-chain (FLC) testing. The exclusion criteria were as follows: Presence of mental disorders; Presence of mental disorders; Pregnancy or lactation; Pregnancy or lactation; Completion of early 99mTc-PYP imaging only, without delayed planar imaging or SPECT imaging; Completion of early 99mTc-PYP imaging only, without delayed planar imaging or SPECT imaging; Claustrophobia. Claustrophobia. The study flowchart is presented in detail in the research workflow diagram. All enrolled patients provided written informed consent, and the study protocol was reviewed and approved by the hospital ethics committee, with the ethics approval number 2025-050-02. Image acquisition 99mTc-PYP imaging was performed using an Optima NM/CT 640 SPECT/CT system. The imaging protocol was conducted in accordance with the recommendations of the American Society of Nuclear Cardiology (ASNC) and the technical guidelines issued by the Cardiac Amyloidosis Working Group of the Chinese Society of Nuclear Medicine [9]. Detailed acquisition parameters are summarized in Table 1. All patients underwent imaging strictly according to the predefined standardized protocol. Table 1Equipment and Scanning ParametersSPECT/CT scannerOptima NM/CT 64099Tcm-PYP Injection Dosage740MBqScanning Phase1-hour and 3-hour planar and tomographic imagingMatrix256 × 256CollectionVertical mode 180°, 3°/frame, 40s/frameEnergy Window140 keV(±10.0%)Magnification1.0CT tube voltage120 kVPipe current10 mA Equipment and Scanning Parameters The acquired imaging data were transferred to a dedicated post-processing workstation for analysis. Image interpretation was performed independently by two experienced nuclear medicine physicians. In cases of discrepant interpretations, images were reviewed in consultation with a senior physician until a consensus was reached. The final imaging results were established by agreement among the reviewers. Prior to image interpretation, all clinical information of the patients was fully masked, and the image reviewers independently conducted the assessments under blinded conditions. Image analysis The three image analysis methods used in this study were consistent with current domestic and international expert consensus. The first method was the semi-quantitative Perugini visual scoring system [11], which compares myocardial tracer uptake with rib uptake. A score of 0 was assigned when normal rib uptake was present in the absence of myocardial uptake. Scores of 1, 2, and 3 were assigned when myocardial uptake was less than, equal to, or greater than rib uptake, respectively. Scores of 0–1 were considered negative for 99mTc-PYP imaging, whereas scores of 2–3 were considered positive. The second method was a semi-quantitative analysis [12] based on the heart-to-contralateral lung (H/CL) uptake ratio, defined as the ratio of the mean counts within a region of interest (ROI) over the heart to the mean counts within an ROI over the contralateral lung. As shown in Figure 1, a circular ROI was drawn on the early planar images to encompass the cardiac region as completely as possible while avoiding the sternum and ribs with prominent tracer uptake. This ROI was then mirrored to a symmetrical ROI over the contralateral chest. The ROIs defined on the early images were subsequently copied onto the delayed planar images to ensure consistency in ROI size and placement between time points. An H/CL ratio ≥ 1.5 was considered indicative of ATTR-CA. Given that radiotracer activity decreases over time, when delayed imaging was used for H/CL ratio assessment, a positive result was defined as an H/CL ratio ≥ 1.3. Draw a circular region of interest (ROI) on the heart in the early and delayed imaging planes, then mirror it to the corresponding ROI on the opposite chest wall The third method was a semi-quantitative scoring approach based on SPECT imaging [13], in which myocardial uptake relative to rib uptake was graded on a scale from 0 to 3. Grade 0 indicated the absence of myocardial uptake with normal bone uptake; grade 1 indicated myocardial uptake less than rib uptake; grade 2 indicated myocardial uptake equal to rib uptake; and grade 3 indicated myocardial uptake greater than rib uptake, with minimal or absent rib uptake. A SPECT semi-quantitative score ≥ 2 was considered positive for 99mTc-PYP imaging. Statistical analysis Statistical analyses were performed using SPSS software (version 19.0). Categorical variables were analyzed using the χ² test and are presented as numbers and percentages [n (%)]. Continuous variables are expressed as mean ± standard deviation (mean ± SD). Intergroup differences in continuous variables among multiple groups were evaluated using one-way analysis of variance (ANOVA) followed by Bonferroni post hoc correction, while comparisons between two groups were performed using the t-test. Inter-method and inter-observer agreement for categorical data were assessed using the Kappa test. Differences in diagnostic performance among the various diagnostic methods were compared using the paired χ² test (McNemar test). A P value < 0.05 was considered statistically significant. To evaluate the incremental diagnostic contribution of SPECT/CT over planar imaging, pairwise comparisons were performed between each corresponding imaging method (e.g., 1-h planar vs. 1-h SPECT, 3-h planar vs. 3-h SPECT, 1-h SPECT vs. 3-h SPECT). McNemar’s test was applied to assess statistically significant differences in paired sensitivity and specificity. The incremental diagnostic yield was calculated as the proportion of patients who were correctly reclassified by SPECT/CT but incorrectly classified by planar imaging. Result Clinical-related results Among the 98 patients with suspected cardiac amyloidosis (CA), 35 were diagnosed with CA, including 12 cases of transthyretin cardiac amyloidosis (ATTR-CA) and 23 cases of light-chain cardiac amyloidosis (AL-CA), while the remaining 63 patients were classified as non-CA. No statistically significant difference was observed in sex distribution among the three groups (P > 0.05). Patients in the ATTR-CA group were significantly older than those in the AL-CA group (P < 0.05). Echocardiographic analysis revealed a statistically significant difference among the three groups in the proportion of patients with a left ventricular wall thickness > 12 mm (χ² = 6.8, P < 0.05). Late gadolinium enhancement on cardiac magnetic resonance imaging (CMR) was more frequently observed in both the ATTR-CA and AL-CA groups compared with the non-CA group (P < 0.05). In addition, the proportion of patients with NT-proBNP levels > 450 ng/L was significantly higher in the CA group than in the non-CA group (P < 0.05). Detailed results are summarized in Table 2. Table 2Comparison of General Characteristics and Selected Examination Results Among 98 Patients Undergoing 99Tcm-PYP ImagingProjectATTR-CA group (n = 12)AL-CA Group (n = 23)Non-CA group (n = 63)TotalInspection valueP-valueGender (Male/Female)8/415/841/2264/34χ2 = 0.5>0.05Age(year, ¯x ± s)67.3 ± 4.156.5 ± 9.861.5 ± 16.659.3 ± 10.2F = 8.2<0.001aEchocardiogram showing wall thickness (>12 mm) (Example)10193766χ2 = 6.8<0.05Delayed Enhancement in Contrast-Enhanced Magnetic Resonance Imaging (CMR) (Example)9214575χ2 = 4.5<0.05Small amount of fluid in the pericardial cavity (Example)6141434χ2 = 10.2<0.01NT-ProBNP(ng/L)>450(Example)10213566χ2 = 8.3<0.05Note: A indicates Bonferroni correction, with P < 0.016 signifying statistical significance. CA: denotes cardiac amyloidosis; AL-CA: refers to light chain cardiac amyloidosis; ATTR-CA: denotes transthyretin-related cardiac amyloidosis Comparison of General Characteristics and Selected Examination Results Among 98 Patients Undergoing 99Tcm-PYP Imaging Note: A indicates Bonferroni correction, with P < 0.016 signifying statistical significance. CA: denotes cardiac amyloidosis; AL-CA: refers to light chain cardiac amyloidosis; ATTR-CA: denotes transthyretin-related cardiac amyloidosis Results of Dual-Time-Point 99mTc-PYP Planar and Tomographic Imaging in Each Group. As shown in Table 3, using the diagnostic gold standard as the reference, semi-quantitative analysis of planar imaging demonstrated that the proportions of positive cases with an early heart-to-contralateral lung (H/CL) ratio ≥ 1.5 were 7/12 (58.3%) in the ATTR-CA group, 2/23 (8.7%) in the AL-CA group, and 1/63 (1.6%) in the non-CA group. On delayed planar imaging, positive cases with an H/CL ratio ≥ 1.3 were observed in 8/12 patients (66.7%) in the ATTR-CA group, whereas no positive cases were identified in either the AL-CA or non-CA groups. Table 3Positive multiparametric imaging results in three groups of patientsGroupEarly imaging H/CL ≥ 1.5 positive casesDelayed imaging H/CL ≥ 1.3 positive casesEarly perugini score ≥ 2 positive casesDelayed perugini score ≥ 2 number of positive casesEarly fracture risk score ≥ 2 number of positive casesDelayed CT score ≥ 2 positive casesATTR-CA group (n = 12)789101012AL-CA Group (n = 23)207010Non-CA group (n = 63)109303Note: CA: denotes cardiac amyloidosis; AL-CA: denotes light chain cardiac amyloidosis; ATTR-CA: denotes transthyretin-related cardiac amyloidosis Positive multiparametric imaging results in three groups of patients Note: CA: denotes cardiac amyloidosis; AL-CA: denotes light chain cardiac amyloidosis; ATTR-CA: denotes transthyretin-related cardiac amyloidosis Based on the Perugini visual grading system, the proportions of positive cases (score ≥ 2) on early planar imaging were 9/12 (75.0%) in the ATTR-CA group, 7/23 (30.4%) in the AL-CA group, and 9/63 (14.3%) in the non-CA group. Identical proportions were observed on delayed planar imaging, with positive cases of 9/12 (75.0%) in the ATTR-CA group, 7/23 (30.4%) in the AL-CA group, and 9/63 (14.3%) in the non-CA group. For tomographic imaging, the proportions of positive cases with a semi-quantitative score ≥ 2 on early SPECT imaging were 10/12 (83.3%) in the ATTR-CA group, 1/23 (4.3%) in the AL-CA group, and none in the non-CA group. On delayed SPECT imaging, the corresponding proportions increased to 11/12 (91.7%) in the ATTR-CA group, while no positive cases were observed in the AL-CA group and 3/63 (4.8%) positive cases were identified in the non-CA group. Diagnostic Performance of Dual‑Time‑Point 99mTc‑PYP Planar and Tomographic Imaging for ATTR‑CA. As summarized in Table 4, delayed SPECT imaging demonstrated the highest diagnostic performance for ATTR‑CA, with a sensitivity of 100.0%, specificity of 96.5%, positive predictive value (PPV) of 80.0%, negative predictive value (NPV) of 100.0%, and an overall accuracy of 96.9%. Early SPECT imaging also showed high diagnostic performance, with a sensitivity of 83.3%, specificity of 98.8%, PPV of 90.9%, NPV of 97.7%, and accuracy of 96.9%. Table 499Tcm- Efficacy of PYP dual-time-point Planar Imaging and Tomographic Imaging for Diagnosing ATTR-CA (Ranked by Diagnostic Efficacy) Comparison (%)IndicatorSensitivity (95%CI)Specificity (95%CI)Positive predictive value (95%CI)Negative predictive value (95%CI)Accuracy(95%CI)Delayed CT score ≥ 2100.0(79.4–100.0)96.5(91.2–98.9)80.0(58.4–93.3)100.0(95.8–100.0)96.9(91.3–98.5)Early fracture risk score ≥ 283.3(55.2–93.3)98.8(96.1–99.9)90.9(60.2–97.5)97.7(95.8–99.8)96.9(91.3–98.5)Delayed Perugini score ≥ 283.3(55.2–93.3)96.5(91.2–98.9)76.9(46.2–88.5)97.6(94.9–99.6)94.9(87.5–96.8)Early Perugini score ≥ 275.0(42.4–86.4)81.4(78.6–90.7)36.0(19.2–56.4)95.8(93.2–99.8)80.6(71.1–86.7)Delayed imaging H/CL ≥ 1.366.6(40.3–86.9)100.0(96.1–100.0)100.0(68.4–100.0)95.5(95.6–99.9)95.9(88.9–97.7)Early imaging H/CL ≥ 1.558.3(35.0-83.8)96.5(91.2–98.9)70.0(37.4–90.0)94.3(93.7–99.6)91.8(83.5–95.1)Note: PYP denotes pyrophosphate; H/CL indicates the uptake ratio between the heart and the contralateral lung; CA: represents cardiac amyloidosis; AL-CA: denotes light chain cardiac amyloidosis; ATTR-CA: refers to transthyretin-related cardiac amyloidosis; confidence intervals are calculated based on the Clopper-Pearson exact binomial distribution, expressed as percentages rounded to one decimal place 99Tcm- Efficacy of PYP dual-time-point Planar Imaging and Tomographic Imaging for Diagnosing ATTR-CA (Ranked by Diagnostic Efficacy) Comparison (%) 96.5 (91.2–98.9) 80.0 (58.4–93.3) 100.0 (95.8–100.0) 96.9 (91.3–98.5) 83.3 (55.2–93.3) 98.8 (96.1–99.9) 90.9 (60.2–97.5) 97.7 (95.8–99.8) 96.9 (91.3–98.5) 83.3 (55.2–93.3) 96.5 (91.2–98.9) 76.9 (46.2–88.5) 97.6 (94.9–99.6) 94.9 (87.5–96.8) 75.0 (42.4–86.4) 81.4 (78.6–90.7) 36.0 (19.2–56.4) 95.8 (93.2–99.8) 80.6 (71.1–86.7) 66.6 (40.3–86.9) 100.0 (96.1–100.0) 95.5 (95.6–99.9) 95.9 (88.9–97.7) 58.3 (35.0-83.8) 96.5 (91.2–98.9) 70.0 (37.4–90.0) 94.3 (93.7–99.6) 91.8 (83.5–95.1) Note: PYP denotes pyrophosphate; H/CL indicates the uptake ratio between the heart and the contralateral lung; CA: represents cardiac amyloidosis; AL-CA: denotes light chain cardiac amyloidosis; ATTR-CA: refers to transthyretin-related cardiac amyloidosis; confidence intervals are calculated based on the Clopper-Pearson exact binomial distribution, expressed as percentages rounded to one decimal place Using the Perugini visual grading system, delayed imaging achieved a sensitivity of 83.3%, specificity of 96.5%, PPV of 76.9%, NPV of 97.6%, and accuracy of 94.9%. In contrast, early Perugini visual grading yielded a sensitivity of 75.0%, specificity of 81.4%, PPV of 36.0%, NPV of 95.8%, and accuracy of 80.6%. With the heart‑to‑contralateral lung (H/CL) method, delayed imaging yielded a sensitivity of 66.6%, specificity of 100.0%, PPV of 100.0%, NPV of 95.7%, and accuracy of 95.9%. Early H/CL‑based assessment demonstrated a lower sensitivity of 58.3%, specificity of 96.5%, PPV of 70.0%, NPV of 94.3%, and overall accuracy of 91.8%. As summarized in Table 5 Pairwise comparisons were performed to evaluate diagnostic agreement across different acquisition time points and imaging modalities. An early SPECT score of 2 demonstrated almost perfect agreement with both the delayed Perugini score ≥ 2 and the delayed H/CL ratio ≥ 1.3 (Kappa > 0.80). High agreement was also observed between the delayed SPECT score of 2 and each of the following parameters: the early SPECT score of 2, the delayed Perugini score ≥ 2, the delayed H/CL ratio ≥ 1.3, as well as between the early SPECT score of 2 and the early H/CL ratio ≥ 1.5, and between the delayed Perugini score ≥ 2 and the delayed H/CL ratio ≥ 1.3 (0.60 < Kappa ≤ 0.80). Moderate agreement was found between the delayed SPECT score of 2 and the early H/CL ratio ≥ 1.5, and between the early SPECT score of 2 and the early Perugini score ≥ 2. Only fair agreement was observed between the delayed SPECT score of 2 and the early Perugini score ≥ 2, between the delayed Perugini score ≥ 2 and the early Perugini score ≥ 2, and between the early Perugini score ≥ 2 and the early H/CL ratio ≥ 1.5 (0.20 < Kappa ≤ 0.60). Table 5Pairwise comparisons of six diagnostic indicators for diagnosing ATTR-CAIndicatorKappa value1 vs. 20.7351 vs. 30.6661 vs. 40.3201 vs. 50.6591 vs. 60.4982 vs. 30.8102 vs. 40.4082 vs. 50.8262 vs. 60.6263 vs. 40.3623 vs. 50.7353 vs. 60.5574 vs. 50.4124 vs. 60.2985 vs. 60.756Note: Indicator 1 = delayed SPECT score of 2; Indicator 2 = early SPECT score of 2; Indicator 3 = delayed Perugini score ≥ 2; Indicator 4 = early Perugini score ≥ 2; Indicator 5 = delayed H/CL ratio ≥ 1.3; Indicator 6 = early H/CL ratio ≥ 1.5 Pairwise comparisons of six diagnostic indicators for diagnosing ATTR-CA Note: Indicator 1 = delayed SPECT score of 2; Indicator 2 = early SPECT score of 2; Indicator 3 = delayed Perugini score ≥ 2; Indicator 4 = early Perugini score ≥ 2; Indicator 5 = delayed H/CL ratio ≥ 1.3; Indicator 6 = early H/CL ratio ≥ 1.5 Pairwise McNemar tests demonstrated that 1-h SPECT significantly improved sensitivity compared with 1-h planar imaging (1/12 reclassified, P < 0.05). Similarly, 3-h SPECT provided the largest incremental diagnostic yield, correctly reclassifying 2/12 ATTR-CA patients missed by 3-h planar imaging (P < 0.05). Delayed SPECT also significantly outperformed early SPECT, resulting in 2/12 additional true-positive detections (P < 0.05). No significant incremental value was observed between early and delayed Perugini scoring or H/CL ratios. These findings highlight the clear diagnostic superiority of delayed SPECT/CT. Overall, SPECT/CT provided statistically significant incremental diagnostic benefit at both imaging time points, with the highest added value observed for 3-h SPECT/CT (incremental yield + 16.7%). These results confirm that tomographic imaging more effectively distinguishes true myocardial uptake from blood-pool activity. Typical ATTR‑CA patients exhibited satisfactory and consistent tracer uptake patterns on both planar and tomographic imaging modalities (Figs. 2 and 3). However, in patients with atypical imaging presentations, careful attention to tomographic imaging findings was essential for accurate diagnosis (Figs. 4 and 5). Front Position CT Fusion of Fractures Front Position CT Fusion of Fractures Figure 2/Figure 3: Same ATTR-CA positive patient. Figure 2 shows SPECT/CT planar images at 1 h and 3 h post-tracer injection, both scoring 3 on the Perugini scale. Clear tracer distribution in the cardiac region is evident, significantly exceeding rib uptake. Figure 3 shows SPECT/CT tomographic and fusion images 3 h post-injection. The tomographic scan scored 3 points, revealing marked circumferential myocardial uptake with myocardial uptake exceeding rib uptake. Rib uptake was minimal, and no distinct tracer distribution was observed in the blood pool. Figure 4/Figure 5: Same ATTR-CA positive patient. Figure 4 shows SPECT/CT planar images at 1 and 3 h post-injection with Perugini scores of 0, revealing no tracer distribution in the cardiac region, significantly lower than rib uptake; Figure 5 shows SPECT/CT tomographic and fusion images 3 h post-injection. The tomographic scan scored 2 points, revealing circumferential myocardial wall uptake equal to that of the ribs, with no apparent tracer distribution in the blood pool.The planar scan scored 0 points using the Perugini method, while the tomographic scan scored 2 points. Discussion The results of this study demonstrate that dual-time-point 99Tcm-PYP planar imaging combined with tomographic imaging has substantial clinical value in the diagnosis of ATTR-CA. Delayed imaging outperforms early imaging, and delayed tomographic imaging not only enhances diagnostic sensitivity but also effectively reduces false-positive findings caused by residual blood-pool activity. Consequently, it significantly improves the accuracy of subtype differentiation. These findings underscore the clear clinical relevance of this imaging approach. In 2018, ATTR-CA was classified as a form of idiopathic cardiomyopathy and included in the national list of 121 rare diseases [3]. Nevertheless, despite its designation as a rare condition, growing evidence in recent years suggests that the true incidence of ATTR-CA has been substantially underestimated. Recent epidemiological data indicate that, in the United Kingdom, the incidence of ATTR-CA increased from 0.75 to 1.96 per 100,000 population between 2004 and 2021, while the number of newly diagnosed cases rose by 2.9-fold during the same period [14]. An increasing body of research now supports the notion that the prevalence of ATTR-CA has historically been underestimated and that it may represent a potentially common disease. Consequently, optimizing noninvasive imaging modalities for differential diagnosis is crucial for achieving accurate and timely identification of this condition. Figure 6 demonstrates the distribution of positive cases across six diagnostic dimensions among the three patient groups. Overall, the ATTR-CA group showed a clear predominance across all imaging modalities. In particular, the greatest number of positive findings occurred in the delayed imaging dimensions, including delayed tomographic scores ≥ 2 and delayed Perugini scores ≥ 2, with 12 and 10 positive cases, respectively, underscoring the pivotal role of delayed imaging in enhancing diagnostic sensitivity. In contrast, the AL-CA and non-CA groups exhibited occasional mild radiotracer uptake on early imaging, mainly reflected by early Perugini scores ≥ 2 (7 cases in the AL-CA group and 9 cases in the non-CA group). However, these findings were almost entirely absent on delayed imaging, indicating that delayed imaging effectively mitigates false-positive results. Diagnostic performance comparison across six 99mTc-PYP imaging approaches. The bar chart displays five key diagnostic indicators—sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy—for the following methods: delayed SPECT, early SPECT, delayed Perugini score, early Perugini score, delayed H/CL ratio, and early H/CL ratio. Delayed SPECT demonstrates superior overall diagnostic performance, achieving the highest sensitivity and accuracy, whereas early H/CL shows the lowest sensitivity among all evaluated techniques. This comparative visualization highlights the diagnostic advantages of delayed SPECT/CT and underscores the limitations of planar H/CL assessment performed at early time points A delayed tomographic imaging score ≥ 2 demonstrated the highest positivity rate in the ATTR-CA group, while only a limited number of false-positive cases were observed in the non-CA group (n = 3), confirming its superiority in mitigating blood-pool–related artifacts. On delayed imaging, an H/CL ratio ≥ 1.3 yielded no positive cases in either the non-CA or AL-CA groups, indicating a substantial improvement in diagnostic specificity and consistency with current clinical recommendations. Although early imaging maintained relatively high sensitivity in identifying ATTR-CA, residual blood-pool activity led to a proportion of false-positive findings in the non-CA and AL-CA groups, thereby diminishing diagnostic reliability. Overall, the imaging results were concordant with the statistical analyses, demonstrating that delayed imaging—particularly delayed SPECT/CT tomographic imaging—offers the most robust diagnostic performance for ATTR-CA. This approach not only enhances diagnostic sensitivity but also markedly reduces false-positive rates. Accordingly, routine integration of delayed SPECT/CT tomographic imaging into standardized clinical diagnostic workflows is strongly recommended. Previous international studies have demonstrated that, among 1-hour and 3-hour planar and tomographic imaging protocols, 3-hour SPECT/CT yields the highest proportion of definitive interpretations, superior image quality, and constitutes the preferred imaging strategy for evaluating unselected patients with clinical suspicion of cardiac amyloidosis [15]. These observations are largely consistent with the findings of the present study, in which 3-hour delayed SPECT/CT tomographic imaging exhibited the highest diagnostic sensitivity and overall accuracy. Moreover, the present study expands on existing evidence by evaluating the diagnostic performance of 1-hour SPECT/CT tomographic imaging. Although its diagnostic efficacy was slightly inferior to that of 3-hour delayed SPECT/CT, 1-hour SPECT/CT consistently outperformed both 1-hour and 3-hour planar imaging across multiple diagnostic indices, underscoring the added value of tomographic imaging even at earlier time points. Our additional pairwise analyses demonstrated that SPECT/CT contributed substantial incremental diagnostic value beyond planar imaging, particularly at the delayed time point. While early (1-h) SPECT modestly improved sensitivity, the greatest benefit was observed for 3-h SPECT/CT, which correctly reclassified 16.7% of ATTR-CA cases that were missed on earlier imaging. These results confirm prior evidence that the superiority of delayed tomographic imaging arises from improved blood-pool clearance and enhanced myocardial-to-background contrast. Therefore, routine inclusion of 3-h SPECT/CT in the diagnostic workflow is strongly recommended. In addition, domestic studies have shown that absolute quantification of myocardial tracer uptake using quantitative SPECT can substantially improve the objectivity and reliability of 99mTc-PYP scintigraphy [16]. When integrated with attenuation and partial-volume correction, quantitative SPECT not only addresses limitations of visual interpretation on planar imaging—particularly in scenarios involving intense extracardiac uptake or overlap between myocardial uptake and blood-pool or skeletal activity—but also provides an objective, quantitative approach for assessing myocardial amyloid burden. Taken together, findings from both international and domestic studies are in close alignment with the results of the present investigation. Regardless of imaging modality, 3-hour delayed imaging demonstrates a clear advantage in the diagnosis of ATTR-CA, with the superiority of tomographic imaging being especially pronounced. Although quantitative analysis was not performed in this study, comparison with previously reported quantitative SPECT data further supports the clinical and diagnostic value of SPECT/CT tomographic imaging in ATTR-CA. Early planar imaging demonstrates acceptable sensitivity but relatively low specificity. Mild radiotracer uptake may be observed in some patients with AL-CA and non-CA, likely due to artifacts caused by residual blood-pool activity following intravenous tracer administration, thereby compromising diagnostic reliability. In contrast, delayed imaging allows for more complete clearance of blood-pool radioactivity, resulting in improved myocardium-to-background contrast. Consequently, the diagnostic performance of delayed planar imaging is markedly superior to that of early imaging. Furthermore, delayed tomographic imaging plays a critical role in accurately identifying true myocardial uptake and excluding artifacts related to blood-pool activity and valvular calcification. In the present study, delayed SPECT/CT achieved a sensitivity of 100% for the diagnosis of ATTR-CA, which was substantially higher than that of early planar imaging and demonstrated high diagnostic concordance. This finding is highly consistent with the nonbiopsy diagnostic strategy for ATTR-CA proposed by Gillmore et al. [17]. Supporting evidence from international studies indicates that, at 4 h after tracer administration, less than 9.5% of 99mTc-PYP remains distributed in the blood, with less than 31.7% in the urine and less than 58.8% in bone and other tissues [18]. These pharmacokinetic characteristics provide a plausible explanation for the superior diagnostic performance of delayed imaging compared with early imaging observed in the present study. Based on the statistical results, early H/CL exhibited the lowest sensitivity in this study. This finding may be partly explained by the similarity between tracer activity in the blood pool and that in the ribs and surrounding soft tissues during the early imaging phase, resulting in a relatively low H/CL ratio. Additionally, suboptimal delineation of the cardiac region of interest—particularly when the region is drawn close to the sternum—may further contribute to underestimation of the H/CL ratio. These factors underscore the importance of accurate identification of the cardiac surface projection when performing H/CL measurements. Accordingly, we propose that the H/CL ratio should be interpreted in conjunction with the Perugini score and tomographic imaging findings rather than used as a standalone metric. This further emphasizes that H/CL values must be integrated with visual image interpretation to avoid misdiagnosis arising from overreliance on a single quantitative parameter. The results indicated that the Perugini score on early imaging and delayed tomographic imaging yielded the highest sensitivity, with delayed tomographic imaging demonstrating superior specificity. In early planar imaging, both the H/CL semiquantitative ratio and the Perugini visual scoring method showed higher sensitivity than delayed planar imaging; however, delayed planar imaging exhibited higher specificity than early planar imaging, while no significant difference in overall diagnostic accuracy was observed between the two approaches. These findings are most likely attributable to tracer accumulation within the cardiac blood pool or myocardial wall during the early imaging phase. With prolonged imaging time, progressive tracer clearance occurs—particularly from the cardiac blood pool—thereby reducing overlap between blood-pool activity and true myocardial uptake. This temporal change substantially affects both the H/CL semiquantitative ratio and the Perugini visual score, resulting in decreased sensitivity but a corresponding improvement in specificity. In summary, the present study demonstrates that both planar and tomographic imaging show relatively high radiotracer uptake in patients with ATTR-CA. However, false-positive findings were observed with early planar semiquantitative scoring and Perugini visual assessment, consistent with reports from both domestic and international studies [19]. Notably, in the early stages of ATTR-CA, planar imaging at different time points was unable to reliably identify positive cases, whereas delayed tomographic imaging clearly demonstrated myocardial tracer uptake. These findings indicate that, in patients with a high clinical suspicion of ATTR-CA or in those with equivocal early imaging results—where diagnostic confidence is limited and ATTR-CA cannot be definitively excluded—the inclusion of tomographic imaging, particularly delayed SPECT/CT, is essential within the diagnostic workflow. Delayed tomographic imaging substantially reduces the risk of missed diagnoses caused by confounding factors during early imaging. Accordingly, we recommend that delayed SPECT/CT tomographic imaging be routinely incorporated into standard noninvasive diagnostic algorithms for ATTR-CA. Especially for patients with equivocal early planar imaging results, we strongly recommend a dual time-point imaging protocol that routinely incorporates delayed SPECT/CT. The present study also highlights the limitations of 99mTc-PYP scintigraphy in the diagnosis of mixed-type cardiac amyloidosis. Although mixed-type CA was not formally included in the study cohort, cases of mixed CA misdiagnosed as ATTR-CA were encountered during the study process. Moreover, previous reports have indicated that a subset of patients with AL-CA may demonstrate myocardial radiotracer uptake, potentially resulting in false-positive findings [20]. Therefore, comprehensive evaluation—including serum and urine immunofixation electrophoresis as well as serum free light-chain assays—is essential in the diagnostic workup of suspected ATTR-CA to avoid misclassification. Several limitations of this study should be acknowledged. First, the retrospective single-center design and relatively small sample size may limit the generalizability of the findings. Second, genetic subtype analysis and long-term prognostic follow-up were not performed. Future studies will focus on expanding the sample size and conducting multicenter prospective investigations, including parallel evaluation of ATTRm and ATTRwt subtypes. In addition, integration of serum protein biomarkers for disease classification and prognostic assessment will be pursued, along with long-term outcome studies of noninvasive diagnostic strategies. Further research will also explore the associations between 99mTc-PYP imaging parameters, the risk of cardiac functional deterioration, and clinical outcomes. Conclusion Dual-time-point 99mTc-PYP planar imaging combined with tomographic imaging demonstrates substantial clinical value in the diagnosis of ATTR-CA. Among these modalities, delayed tomographic imaging offers the optimal diagnostic performance, significantly enhancing diagnostic accuracy while effectively reducing false-positive findings attributable to blood-pool artifacts. Furthermore, an integrated assessment incorporating the Perugini visual score and the H/CL ratio provides a robust and reliable basis for the early diagnosis and subtype differentiation of cardiac amyloidosis. Delayed SPECT/CT provides optimal diagnostic value, and early SPECT may be considered in specific clinical situations, providing practical workflow recommendations to balance diagnostic performance and laboratory efficiency. This comprehensive, noninvasive diagnostic strategy has the potential to inform future clinical practice and support refinement of diagnostic guidelines. Acknowledgements Not applicable. Abbreviations Cardiac amyloidosis Transthyretin amyloid cardiomyopathy Transthyretin amyloid hereditary Transthyretin amyloid wild-type Heart-to-contralateral lung uptake ratio Ight-chain-type BASED on transthyretin Mutant-type ATTR-CA The American Society of Nuclear Cardiology The guidelines of the European Society of Cardiology Urine immunofixation electrophoresis Free light-chain A region of interest One-way analysis of variance Cardiac magnetic resonance imaging Positive predictive value Negative predictive value Author contributions J.L. was primarily responsible for data integration and drafting the manuscript. W.Y. contributed to the critical review and revision of the manuscript. T.C was responsible for selecting topics, polishing, and revising papers. L.J. was involved in data analysis. Q.D. and Q.K. contributed to data collection. All authors have reviewed and approved the final manuscript. Funding Study on the Relationship Between Transthyroxine Cardiac Amyloidosis Incidence and Atrial Fibrillation in Plateau Regions(Project Number: 2025YFKT-QN-16). Data availability The data that support the findings of this study are derived from real-world patient records at the participating hospital. Due to privacy and ethical restrictions, they are not publicly available. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Ting Chen, Email: chenting@kmmu.edu.cn. Weihong Yuan, Email: Yuantianhe@163.com. References Associated Data Data Availability Statement The data that support the findings of this study are derived from real-world patient records at the participating hospital. Due to privacy and ethical restrictions, they are not publicly available.